Merck’s deal for Terns sparks debate over a possible biotech bidding war
BioPharma Dive
Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run.
FDA clears Denali drug in ‘clear step’ for rare disease biotechs
BioPharma Dive
The approval of Denali s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA s stance on rare disease therapies.
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
BioPharma Dive
Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.
Maze tumbles despite positive data for kidney disease drug
BioPharma Dive
Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.
Beam posts positive data on base editing treatment for AATD
BioPharma Dive
Updated data showed the biotech’s approach to the rare lung and liver condition helped restore functional protective proteins in a small study.
Sarepta sees early success with RNAi drugs from Arrowhead
BioPharma Dive
Long-awaited results from Phase 1/2 studies lifted Sarepta s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
BioPharma Dive
If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.
Karyopharm myeloma drug yields mixed data in myelofibrosis trial
BioPharma Dive
Xpovio combined with Incyte s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst s estimates, could triple the company s revenue.
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
BioPharma Dive
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.
RA Capital targets China with latest SPAC deal
BioPharma Dive
The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.
Immutrin raises $87M to advance drug for progressive heart disease
BioPharma Dive
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, ATTR-CM, that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares
BioPharma Dive
Industry executives can share their views on the national priority program at a June meeting.
NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
Drug Channels
I am pleased to announce Drug Channels Institute’s new 2026 Economic Report on U.S.
How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
BioPharma Dive
Cohen says he looked at around two dozen companies since Acorda wound down.
Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
BioPharma Dive
The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.
Apogee strengthens case for longer-lasting eczema drug
BioPharma Dive
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.